Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS): first analysis on survival

Ito, Kazuto; Saito, Shiro; Yorozu, Atsunori; Kojima, Shinsuke; Kikuchi, Takashi; Higashide, Satoshi; Aoki, Manabu; Koga, Hirofumi; Satoh, Takefumi; Ohashi, Toshio; Nakamura, Katsumasa; Katayama, Norihisa; Tanaka, Nobumichi; Nakano, Masahiro; Shigematsu, Naoyuki; Dokiya, Takushi; Fukushima, Masanori; Investigators, J-Pops

doi:10.1007/s10147-018-1309-0

Cited by 25 publications

(27 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, another large-scale study in the USA determined excellent long-term outcomes with modern LDR brachytherapy in patients at low-, intermediate-, and high-risk [ 26 ]. For LDR brachytherapy as monotherapy, long-term benefits comparable to those described here have been reported across all risk groups in various regions of the world including UK [ 27 ], USA [ 5 , 28 ], France [ 29 ], China [ 30 ], and Japan [ 31 ]. Similarly to the results of this study, superior bPFS rates of brachytherapy compared to those predicted with Kattan nomograms (pre and post-operative) have also been reported for a patient cohort in Israel, which was however smaller and mainly consisted of low-risk patients [ 32 ].…”

Section: Discussionsupporting

confidence: 63%

Five-year effectiveness of low-dose-rate brachytherapy: comparisons with nomogram predictions in patients with non-metastatic prostate cancer presenting significant control of intra- and periprostatic disease

Zimmermann

Osieka

Bruns³

et al. 2018

jcb

View full text Add to dashboard Cite

PurposeTo assess the effectiveness of low-dose-rate (LDR) brachytherapy in patients with localized prostate cancer and to compare the outcome with predictions from Kattan and Partin nomograms at 60 months after seed implantation.Material and methodsOne thousand, one hundred and eighty-seven patients with localized prostate cancer at low-, intermediate-, or high-risk of progression received LDR brachytherapy using iodine-125 seeds with curative intent, applied as monotherapy or in combination with external beam radiation therapy (EBRT), and/or androgen deprivation therapy (ADT). At 60 months after seed implantation, data of 1,064 patients (1,058 alive + 6 who died of prostate cancer) were analyzed for biochemical progression-free survival (bPFS) based on prostate-specific antigen (PSA) levels using the Phoenix definition. Five-year bPFS probabilities were determined for various risk group classifications (d’Amico, Mt. Sinai, MSKCC/Seattle, NCCN). Outcomes were also compared to patient-individualized nomogram predictions of 5-year bPFS (Kattan 2002) and probability of organ-confined disease (Kattan 2002, Partin 2007).ResultsOverall, 93.3% (993/1,064) of the patients were free of biochemical progression within 5 years, while the average 5-year bPFS probability according to the Kattan nomogram was significantly lower (85%, p < 0.001). Outcomes were significantly better than Kattan nomogram predictions in the subgroup of patients with monotherapy as well as in patients additionally treated with EBRT. Comparison of the overall outcome with nomogram predictions for organ-confined disease (Kattan nomogram: 50%; Partin nomogram: 65%) revealed a significant probability of LDR brachytherapy to destroy periprostatic tumor spread (p < 0.001) in all risk group constellations, even in high-risk patients.ConclusionsThe results indicate high effectiveness of LDR brachytherapy in all risk groups, significantly better than predicted with the Kattan nomogram in most subgroups. The significant superiority of LDR brachytherapy compared to nomogram predictions of organ-confined disease suggests that LDR brachytherapy effectively controls both intra- and periprostatic disease.

show abstract

Section: Discussionsupporting

confidence: 63%

Five-year effectiveness of low-dose-rate brachytherapy: comparisons with nomogram predictions in patients with non-metastatic prostate cancer presenting significant control of intra- and periprostatic disease

Zimmermann

Osieka

Bruns³

et al. 2018

jcb

View full text Add to dashboard Cite

show abstract

“…Adverse events treated with i-125 particle brachytherapy are associated with normal tissue radiation exposure, but are usually mild and manageable. Currently, I-125 particle implantation therapy has been used in a variety of solid tumors, including prostate cancer, pancreatic cancer, lung cancer and head and neck cancer [13][14][15][16].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Iodine-125 Brachytherapy Combined with Hepatectomy: A Meta-analysis

2022

JCMP

View full text Add to dashboard Cite

Objective: To investigate the efficacy and safety of hepatectomy combined with iodine-125 (I-125) seed margin implantation in the treatment of hepatocellular carcinoma. Methods: The databases such as PubMed, Cochrane Library, Embase, CNKI, CBM and wanfang database were retrieved, and the clinical control study with hepatectomy combined with I-125 seed margin implantation for hepatocellular carcinoma were included. Qualified literatures were included according to the standard, and the literature quality was evaluated by the modified Jadad scale and the Newcastle-Ottawa scale. Meta-analysis was performed using RevMan 5.4 software. Results: Four studies were included, with a total of 252 patients. The results showed that there was no significant difference in 1-year survival rate between the two groups. The 3-year survival rate and 5-year survival rate of the combined treatment group were better than those of the control group. There was no significant difference in the incidence of complications between the two groups. Conclusion: Compared with simple hepatectomy, I-125 seed margin implantation assisted hepatectomy has improved clinical efficacy in the treatment of hepatocellular carcinoma without increasing the incidence of complications.

show abstract

“…J-POPS was a prospective multi-institutional registry study of 2354 patients with predominantly low and intermediate risk disease. Of the 1792 patients who received brachytherapy monotherapy ( + /-ADT), the 5-year bPFS was 89.3% ( 13 ).…”

Section: Multi-institutional Outcomes: Low and Intermediate Riskmentioning

confidence: 99%

Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement

et al. 2021

View full text Add to dashboard Cite

show abstract

Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS): first analysis on survival

Abstract: NCT00534196.

Cited by 25 publications

References 28 publications

Five-year effectiveness of low-dose-rate brachytherapy: comparisons with nomogram predictions in patients with non-metastatic prostate cancer presenting significant control of intra- and periprostatic disease

Five-year effectiveness of low-dose-rate brachytherapy: comparisons with nomogram predictions in patients with non-metastatic prostate cancer presenting significant control of intra- and periprostatic disease

Efficacy and Safety of Iodine-125 Brachytherapy Combined with Hepatectomy: A Meta-analysis

Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement

Contact Info

Product

Resources

About